Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment

Background This study was conducted to evaluate the clinical efficacy and safety of peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTA0-Tyr3-octreotate (DOTATATE) in patients with neuroendocrine tumors (NETs). Methods Sixteen patients with pathologically verified NETs including...

Full description

Bibliographic Details

Published in:	World Journal of Nuclear Medicine
Main Authors:	Mohammadreza Kalantarhormozi, Samaneh Hassanzadeh, Seyed Javad Rekabpour, Mohammad Reza Ravanbod, Esmail Jafari, AbdulLatif Amini, Habibollah Dadgar, Mehdi Mahmoudpour, Iraj Nabipour, Narges Jokar, Majid Assadi
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2022-09-01
Subjects:	neuroendocrine tumors (nets) peptide receptor radionuclide therapy (prrt) 177lu-dotatate 68ga-dotatate pet-ct 99mtc-octreotide scintigraphy
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1755412